keyword
MENU ▼
Read by QxMD icon Read
search

triptans and headaches

keyword
https://www.readbyqxmd.com/read/29143899/headache-in-resource-limited-settings
#1
REVIEW
Yohannes W Woldeamanuel
PURPOSE OF REVIEW: This review summarizes the unmet need of headache burden and management in resource-limited settings. It provides a general overview of the nuances and peculiarities of headache disorders in resource-limited settings. The review delivers perspectives and explanations for the emerging burden of both primary and secondary headache disorders. Important discussion on demographic and epidemiologic transition pertinent to low-resource settings is included. A critical analysis of headache disorders is made within the context of growing burden non-communicable disorders in low-resource countries...
November 16, 2017: Current Pain and Headache Reports
https://www.readbyqxmd.com/read/29101861/clinical-characteristics-and-overuse-patterns-of-medication-overuse-headache-retrospective-case-series-study
#2
Karolis Kluonaitis, Elena Petrauskiene, Kristina Ryliskiene
According to Eurolight project's results, frequency of medication overuse headache in Lithuania is similar to other European countries. However, data on the characteristics of the disorder is lacking. OBJECTIVE: The aim was to analyze clinical characteristics and overuse patterns of patients with medication overuse headache. PATIENTS AND METHODS: Retrospective study was conducted in out-patient department of university hospital. 57.0% of the patients were from Vilnius and 43...
October 31, 2017: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/29062667/hair-transplantation-in-migraine-headache-patients
#3
Safvet Ors
BACKGROUND: Migraine headache is a primary neurologic disease affecting millions of people worldwide. As a consequence, quality of life is diminished, productivity suffers (through loss of work force), and treatment costs are substantial. The occurrence rate in the general population is quite high, with women accounting for 3 of every 4 cases. METHODS: Between January 2011 and May 2012, a total of 221 patients received hair transplants. Another 590 patients underwent hair transplantation between June 2012 and December 2016...
September 2017: Plastic and Reconstructive Surgery. Global Open
https://www.readbyqxmd.com/read/29053129/-medication-overuse-headache
#4
M Yu Maksimova, T Yu Сhochlova, L A Mota
Rebound headache (RH) is a chronic daily headache which occurs when analgesics, triptans, ergotamines are taken frequently (more than 15 days/month for more than 3 months) to relieve headaches. The prevalence of RH is 1 to 4% in the general population. RH commonly occurs in patients with migraine and tension-type headache. The deficit of central sensitization and psychological factors play an important role in initiating and maintaining of RH. Treatment of noofen for 2 months is effective in 75% of patients with RH...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29022755/randomized-double-blind-placebo-controlled-parallel-group-multi-center-study-of-the-safety-and-efficacy-of-adam-zolmitriptan-for-the-acute-treatment-of-migraine
#5
Egilius Lh Spierings, Jan Lewis Brandes, David B Kudrow, James Weintraub, Peter C Schmidt, Donald J Kellerman, Stewart J Tepper
Objective To determine the efficacy, tolerability, and safety of ascending doses of Adhesive Dermally-Applied Microarray (ADAM) zolmitriptan versus placebo for acute migraine treatment. Background ADAM is a novel patient-administered system for intracutaneous drug administration. In a phase 1 pharmacokinetic study, zolmitriptan administered using ADAM had much faster absorption than oral administration with higher exposure in the first two hours. Methods This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2b/3 study evaluating ADAM zolmitriptan 1 mg, 1...
January 1, 2017: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/29019093/triptans-and-cgrp-blockade-impact-on-the-cranial-vasculature
#6
REVIEW
Silvia Benemei, Francesca Cortese, Alejandro Labastida-Ramírez, Francesca Marchese, Lanfranco Pellesi, Michele Romoli, Anne Luise Vollesen, Christian Lampl, Messoud Ashina
The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine...
October 10, 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28990165/framingham-based-cardiovascular-risk-estimates-among-people-with-episodic-migraine-in-the-us-population-results-from-the-american-migraine-prevalence-and-prevention-ampp-study
#7
Richard B Lipton, Michael L Reed, Tobias Kurth, Kristina M Fanning, Dawn C Buse
BACKGROUND: Cardiovascular (CV) events, conditions, and procedures (ECPs) are common in persons with migraine and are a contraindication to triptan and ergot use. In a prior study, we estimated that there are 2.6 million American adults with episodic migraine (EM) who have had CV ECPs. However, the prior analysis did not assess persons with migraine without CV ECPs who are at high risk for a first cardiovascular disease (CVD) event. OBJECTIVES: To use the Framingham nonlaboratory CVD events risk equation to estimate the number of individuals with EM who are at elevated risk for a first CVD event in the next 10 years using data from the American Migraine Prevalence and Prevention Study, and then to extrapolate the findings to the US population to estimate the scope of people with EM for whom triptan and ergot therapies may be problematic...
October 9, 2017: Headache
https://www.readbyqxmd.com/read/28944683/-thoracic-migraine-as-a-new-manifestation-of-migraine-case-report
#8
Torsten Kraya, Stephan Mages, Stephan Zierz
Background and objectives Abdominal pain is a well-known headache-associated symptom in migraine in children, but rarely in adults. We describe a case of a female patient with typical accompanying migraine symptoms without headache but with thoracic pain. Case report The present case of a 41 year-old-woman shows recurrent attacks with thoracic pain and typical accompanying migraine symptoms but without headache. Symptoms resolved upon treatment with triptans and beta blockers. Discussion This case might be interpreted as "thoracic migraine", and extends the spectrum of migraine forms...
January 1, 2017: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/28883254/naratriptan-in-the-prophylactic-treatment-of-cluster-headache
#9
Yasuo Ito, Takashi Mitsufuji, Yoshio Asano, Tomokazu Shimazu, Yuji Kato, Norio Tanahashi, Yuichi Maruki, Fumihiko Sakai, Toshimasa Yamamoto, Nobuo Araki
Objective Naratriptan has been reported to reduce the frequency of cluster headache. The purpose of this study was to determine whether naratriptan is effective as a prophylactic treatment for cluster headache in Japan. Methods We retrospectively reviewed all 43 patients with cluster headache who received preventive treatment with naratriptan from April 2009 to April 2015. The International Classification of Headache Disorders, 3rd Edition (beta version) (ICHD-3 beta) was used to diagnose cluster headache. This study was conducted at 3 centers (Department of Neurology, Saitama Medical University; Saitama Neuropsychiatric Institute; Saitama Medical University International Medical Center)...
October 1, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28878923/a-31-year-old-with-idiopathic-reversible-cerebral-vasoconstriction-syndrome
#10
Ihtesham A Qureshi, Mohtashim A Qureshi, Obiajulu Kanu, Salvador Cruz-Flores
In our patient with reversible cerebral vasoconstriction syndrome (RCVS) syndrome, presenting with thunderclap-like headache, there is a possibility to be readily confused with migraine. Initiating treatment with selective serotonin reuptake inhibitors (SSRIs) and triptans can further aggravate the condition. Therefore, it is essential to understand the nature and type of headache and correlate the clinical findings with imaging studies.
September 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28842849/temporal-relations-in-hormone-withdrawal-migraines-and-impact-on-prevention-a-diary-based-pilot-study-in-combined-hormonal-contraceptive-users
#11
Gabriele S Merki-Feld, Gina Epple, Nina Caveng, Bruno Imthurn, Burkhardt Seifert, Peter Sandor, Andreas R Gantenbein
BACKGROUND: Menstrually related migraine (MRM) in the hormone-free interval (HFI) of combined hormonal contraceptives (CHC) are according to the ICHD definition also estrogen withdrawal migraines (EWH). MRMs are less responsive to acute medication. Therefore short-term prevention, initiated 1-2 days before onset of the anticipated bleeding and continued for 6 days, is recommended. Such a long prophylactic triptan use might increase the risk for medication overuse headache in women suffering in addition from non-menstrual migraines...
August 25, 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28815436/headache-attributed-to-airplane-travel-diagnosis-pathophysiology-and-treatment-a-systematic-review
#12
Sebastian Bao Dinh Bui, Parisa Gazerani
BACKGROUND: Headache attributed to airplane travel, also named "airplane headache" (AH) is a headache that occurs during take-off and landing. Today, there are still uncertainties about the pathophysiology and treatment of AH. This systematic review was performed to facilitate identification of the existing literature on AH in order to discuss the current evidence and areas that remain to be investigated in AH. METHODS: The systematic literature search was performed in 3 relevant medical databases; PubMed, Scopus, and Embase...
August 16, 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28752512/medical-treatment-guidelines-for-preventive-treatment-of-migraine
#13
Tzu-Chou Huang, Tzu-Hsien Lai, Treatment Guideline Subcommittee Of Taiwan Headache Society Taiwan Headache Society
The Treatment Guideline Subcommittee of the Taiwan Headache Society evaluated the medications currently used for migraine prevention in Taiwan. We assessed the results of new published drug trials, information from medical database and referred to the latest guidelines published. After comprehensive discussion, we proposed Taiwanese consensus about the preventive treatment for migraine including recommendation levels, strength of evidences, and related prescription information regarding dosage and adverse effects...
March 15, 2017: Acta Neurologica Taiwanica
https://www.readbyqxmd.com/read/28749698/the-safety-and-efficacy-of-the-5-ht-1f-receptor-agonist-lasmiditan-in-the-acute-treatment-of-migraine
#14
Bianca Raffaelli, Heike Israel, Lars Neeb, Uwe Reuter
Migraine is among the most disabling disorders worldwide, with a significant therapeutic need. Triptans are drugs of choice in the acute attack treatment, but they are contraindicated in patients with vascular conditions due to their potential vasoconstrictive properties. Further limitations include side effects, inconsistency in therapeutic action and possible non-response. Lasmiditan, a highly selective 5-HT1F receptor agonist, is a novel acute anti-migraine substance devoid of vasoconstriction. Areas covered: This article reviews the clinical efficacy and safety of oral and intravenous lasmiditan as a possible acute migraine treatment...
September 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28733943/onabotulinumtoxina-injections-in-chronic-migraine-targeted-to-sites-of-pericranial-myofascial-pain-an-observational-open-label-real-life-cohort-study
#15
Danièle Ranoux, Gaelle Martiné, Gaëlle Espagne-Dubreuilh, Marlène Amilhaud-Bordier, François Caire, Laurent Magy
BACKGROUND: OnabotulinumtoxinA has proven its efficacy in reducing the number of headache days in chronic migraine (CM) patients. The usual paradigm includes 31 pericranial injection sites with low dose (5 U) per site. The aim of this study is to present the results obtained using a simpler injection protocol of onabotulinumtoxinA, with injection sites targeted to pericranial myofascial sites of pain. METHODS: Observational, open label, real-life, cohort study...
December 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28705177/patterns-and-predictors-of-analgesic-use-in-pregnancy-a-longitudinal-drug-utilization-study-with-special-focus-on-women-with-migraine
#16
Gerd-Marie Eskerud Harris, Mollie Wood, Malin Eberhard-Gran, Christofer Lundqvist, Hedvig Nordeng
BACKGROUND: Few studies have investigated the drug utilization patterns and factors predicting drug use in pregnant women with migraine. This longitudinal drug utilization study aimed to describe patterns of analgesic use in a sample of Norwegian pregnant women according to their migraine history, and to identify predictors for analgesic use among these women. METHODS: Pregnant women giving birth at Akershus University Hospital between 2008 and 2010 were recruited at ultrasound examination in gestational week 17...
July 14, 2017: BMC Pregnancy and Childbirth
https://www.readbyqxmd.com/read/28649860/do-racial-ethnic-disparities-exist-in-recommended-migraine-treatments-in-us-ambulatory-care
#17
Larry Charleston Iv, James Francis Burke
Background Racial disparities in migraine have been reported in the US. Migraine in African Americans (AA) is more frequent, more severe, more likely to become chronic and associated with more depression and lower quality of life compared to non-Hispanic Whites (NHW). It is possible that racial differences in prescribing practices contribute to these differences, but little is known about the quality of migraine prescribing patterns in the US or whether racial differences exist. Objective To determine if racial differences in quality of migraine medical prescription care exist...
January 1, 2017: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/28645128/-headache-news
#18
Hans-Christoph Diener, Charly Gaul, Dagny Holle-Lee, Lazaros Lazaridis, Steffen Nägel, Mark Obermann
A review of the latest and most relevant information on different disorders of head and facial pain is presented. News from epidemiologic studies regarding the relationship between migraine and patent foramen ovale, the cardiovascular risk in migraine, and migraine behavior during menopause, and the development of white matter lesions or migraine genetics are presented. Regarding pathophysiology there are very recent insights regarding the role of the hypothalamus during prodromal phase and the interplay of brain-stem and hypothalamus during the attack...
June 2017: Fortschritte der Neurologie-Psychiatrie
https://www.readbyqxmd.com/read/28603893/allodynia-is-associated-with-initial-and-sustained-response-to-acute-migraine-treatment-results-from-the-american-migraine-prevalence-and-prevention-study
#19
Richard B Lipton, Sagar Munjal, Dawn C Buse, Alix Bennett, Kristina M Fanning, Rami Burstein, Michael L Reed
OBJECTIVE: In a population sample of persons with migraine treating with a single category of acute migraine medication, to identify rates and factors associated with acute treatment outcomes, including 2-hour pain freedom (2hPF), 24-hour pain response (24hPR), and 24-hour sustained pain response (24hSPR). Key predictors include acute treatment type (triptans and other medication categories), the influence of allodynia on response to medication, and the interaction between medication category and presence of allodynia in response to treatment among people with migraine...
June 11, 2017: Headache
https://www.readbyqxmd.com/read/28554244/effectiveness-of-the-progestin-only-pill-for-migraine-treatment-in-women-a-systematic-review-and-meta-analysis
#20
Samantha Warhurst, Christopher J Rofe, Bruce J Brew, Deborah Bateson, Kevin McGeechan, Gabriele S Merki-Feld, Raymond Garrick, Susan E Tomlinson
Background Migraine is highly prevalent in women (18%). Peak morbidity affects their most productive years, coinciding with peak fertility. Hormonal contraception is often tailored for migraine prevention. Estrogen-containing contraceptives may be contraindicated in women experiencing migraine with aura due to the risk of vascular events. While improvements in migraine with a progestin-only pill (POP), which inhibits ovulation are documented, the strength and quality of evidence has not been formally evaluated...
January 1, 2017: Cephalalgia: An International Journal of Headache
keyword
keyword
92187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"